Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
Morgan Stanley lowered the firm’s price target on Arvinas (ARVN) to $12 from $48 and keeps an Equal Weight rating on the shares after the ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Zacks Investment Research on MSN18h
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline UpdateNovo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY ...
Zacks Investment Research on MSN22h
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & MoreMergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback